{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:10:01Z","timestamp":1791115801410,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T00:00:00Z","timestamp":1496966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CPT Pharmacom &amp; Syst Pharma"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:p>Sulfadoxine\/pyrimethamine is recommended for intermittent preventative treatment of malaria during pregnancy. Data from 98 women during pregnancy and 77 after delivery in four African countries were analyzed using nonlinear mixed\u2010effects modeling to characterize the effects of pregnancy, postpartum duration, and other covariates such as body weight and hematocrit on sulfadoxine\/pyrimethamine pharmacokinetic properties. During pregnancy, clearance increased 3\u2010fold for sulfadoxine but decreased by 18% for pyrimethamine. Postpartum sulfadoxine clearance decreased gradually over 13 weeks. This finding, together with hematocrit\u2010based scaling of plasma to whole\u2010blood concentrations and allometric scaling of pharmacokinetics parameters with body weight, enabled site\u2010specific differences in the pharmacokinetic profiles to be reduced significantly but not eliminated. Further research is necessary to explain residual site\u2010specific differences and elucidate whether dose\u2010optimization, to address the 3\u2010fold increase in clearance of sulfadoxine in pregnant women, is necessary, viable, and safe with the current fixed dose combination of sulfadoxine\/pyrimethamine.<\/jats:p>","DOI":"10.1002\/psp4.12181","type":"journal-article","created":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T06:28:39Z","timestamp":1496989719000},"page":"430-438","source":"Crossref","is-referenced-by-count":31,"title":["Pharmacokinetics of Sulfadoxine and Pyrimethamine for Intermittent Preventive Treatment of Malaria During Pregnancy and After Delivery"],"prefix":"10.1002","volume":"6","author":[{"given":"M","family":"de Kock","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine University of Cape Town Cape Town South Africa"},{"name":"World Wide Antimalarial Resistance Network (WWARN) Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Tarning","sequence":"additional","affiliation":[{"name":"Mahidol\u2010Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine Mahidol University Bangkok Thailand"},{"name":"Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine University of Oxford Oxford UK"},{"name":"World Wide Antimalarial Resistance Network (WWARN) Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Workman","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine University of Cape Town Cape Town South Africa"},{"name":"World Wide Antimalarial Resistance Network (WWARN) Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MM","family":"Nyunt","sequence":"additional","affiliation":[{"name":"Institute for Global Health, University of Maryland School of Medicine Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Adam","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences Al Neelain University Khartoum Sudan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KI","family":"Barnes","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine University of Cape Town Cape Town South Africa"},{"name":"World Wide Antimalarial Resistance Network (WWARN) Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Denti","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine University of Cape Town Cape Town South Africa"},{"name":"World Wide Antimalarial Resistance Network (WWARN) Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,9]]},"reference":[{"key":"e_1_2_10_1_1","volume-title":"World Malaria Report 2015","author":"World Health Organization"},{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000221"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(07)70021-X"},{"key":"e_1_2_10_4_1","first-page":"932895","article-title":"Parasitologic assessment of two\u2010dose and monthly intermittent preventive treatment of malaria during pregnancy with sulphadoxine\u2010pyrimethamine","volume":"2011","author":"Agomo C.O.","year":"2011","journal-title":"Malar. Res. Treat."},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425251003677755"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0909-7"},{"key":"e_1_2_10_7_1","first-page":"594","article-title":"Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine\u2010pyrimethamine and risk of low birth weight in Africa","volume":"309","author":"Kayentao K.","year":"2003","journal-title":"Clin. Corner."},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.177"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0731-7085(94)00061-1"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015947301890"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21916"},{"key":"e_1_2_10_12_1","unstructured":"Charpiat B.et al. for the Eurotoxo Group (panel 2).Systematic search and analysis of published pharmacokinetic data related to sulfadoxine [Unpublished report]. Bordeaux (France): The Eurotoxo Group;2004."},{"key":"e_1_2_10_13_1","volume-title":"Pharmacokinetics and Pharmacodynamics of Antimalarial Drugs Used in Combination Therapy","author":"Hickman M.R.","year":"2015"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00335-09"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1086\/522632"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.08.016"},{"key":"e_1_2_10_17_1","volume-title":"NONMEM Users Guides (1989\u20102009)","author":"Beal S.","year":"2009"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.48.113006.094708"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012299115260"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-7-149"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.24547"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2013.01.012"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.050245"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1980.tb04501.x"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.4297\/najms.2011.330"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31819e91ce"},{"key":"e_1_2_10_27_1","first-page":"212","article-title":"Application of genomic technologies in clinical pharmacology research","volume":"67","author":"Leon\u2010Cachon R.B.","year":"2015","journal-title":"Rev. Invest. Clin."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph8030637"},{"key":"e_1_2_10_29_1","first-page":"351","article-title":"Trimester\u2010specific population pharmacokinetics and other correlates of variability in sulphadoxine\u2010pyrimethamine disposition among Ugandan pregnant women","volume":"15","author":"Odongo C.O.","year":"2015","journal-title":"Drugs Res. Dev."}],"updated-by":[{"DOI":"10.1002\/psp4.12549","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000}},{"DOI":"10.1002\/psp4.12575","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000}},{"DOI":"10.1002\/psp4.12503","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000}}],"container-title":["CPT: Pharmacometrics &amp; Systems Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpsp4.12181","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.12181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T22:57:31Z","timestamp":1694991451000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/psp4.12181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,9]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1002\/psp4.12181"],"URL":"https:\/\/doi.org\/10.1002\/psp4.12181","archive":["Portico"],"relation":{"erratum":[{"id-type":"doi","id":"10.1002\/psp4.12503","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/psp4.12549","asserted-by":"object"}],"correction":[{"id-type":"doi","id":"10.1002\/psp4.12575","asserted-by":"object"}]},"ISSN":["2163-8306","2163-8306"],"issn-type":[{"value":"2163-8306","type":"print"},{"value":"2163-8306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,9]]}}}